1 / 6

Risk stratification in Pulmonary Embolism and Duration of Anticoagulation

Risk stratification in Pulmonary Embolism and Duration of Anticoagulation. Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE. Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin , BNP High mortality risk > 15%

saul
Télécharger la présentation

Risk stratification in Pulmonary Embolism and Duration of Anticoagulation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Risk stratification in Pulmonary Embolism and Duration of Anticoagulation Respiratory CONNECT meeting Dr Julius Cairn

  2. Risk stratification in PE • Clinical parameters – shock, JVP, S3 • Imaging – CTPA, echo • Biomarkers – Troponin, BNP • High mortality risk > 15% • - shock, RV dysfunction, positive biomarkers – thrombolyse • Intermediate risk 3-15% • RV dysfunction and positive biomarkers – iv heparin • Low risk <1% mortality • Early discharge • Above knee DVT – high risk for post-thrombotic syndrome and for PE • Risk stratification should improve outcome and reduce length of stay

  3. Duration of anticoagulation • Number of studies show no benefit of 6 months over 3 months, also ACCP recommendation • Risk of recurrence returns after stopping • 0.7% per year VTE provoked by surgery • 3% per year for all patients • 7.4% per year for unprovoked event • In order to justify lifelong anticoagulation 5% or greater risk • Consider lifelong anticoagulation in idiopathic PE

  4. Improving outcomes from Community Acquired Pneumonia (CAP) Respiratory CONNECT meeting Dr Julius Cairn

  5. Late mortality from CAP • Leading cause of death from infectious disease in western countries – mortality rate 5-15% • On-going risk of mortality in months/years afterwards • >25% of deaths within 30 days are not directly related • Nearly 50% deaths overall related to comorbidties • Evidence of link between acute respiratory infections and increased risk of cardiovascular events • Incidence after CAP : 15 days – 10.7%, 90days 13%, 1 year 33% • Prior statin or ACEi treatment • Influenza/ Pneumococcal vaccination • Further define if cause of CV events and pathogenesis

  6. How differences in medical management of CAP might influence outcome • Menendes et al multicentre trial of 4,137 pts • Adherence to antibiotic guidelines • Shorter length of stay in patients without organ failure • Delivery of the first dose of antibiotic within 6 hours of presentation • Mortality better in the severe sepsis patients • Measurement of oxygenation at presentation • Doesn’t distinguish between preventable/inevitable mortality BUT medical management influence outcome • Challenge – identify bundles of practice that give best outcomes

More Related